yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q27027751-36B9DAB0-10F8-4894-ABEA-8C7B6648F64C
Q27027751-36B9DAB0-10F8-4894-ABEA-8C7B6648F64C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27027751-36B9DAB0-10F8-4894-ABEA-8C7B6648F64C
Predicting response to epigenetic therapy
P2860
Q27027751-36B9DAB0-10F8-4894-ABEA-8C7B6648F64C
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27027751-36B9DAB0-10F8-4894-ABEA-8C7B6648F64C
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
84a7a0b55f1aea353549bdcce65de00d4f117de5
P2860
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.